Thermo Fisher Scientific (NYSE:TMO) today announced plans to develop two new sterile filling lines in Singapore to extend capacity to the Asia Pacific region for the development and manufacture of therapies and vaccines.
Established with the support of the Singapore Economic Development Board (EDB), the $130M facility will be operated by Thermo Fisher and have the capability to manufacture pharmaceutical products to meet demand in the region and respond effectively to future health emergencies.
Get the full story on our sister site, Drug Discovery & Development.